Navigation Links
Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
Date:9/12/2012

BASKING RIDGE, N.J., Sept. 12, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the UBS Global Life Sciences Conference at 2:00 p.m. ET on September 19, 2012 at the Grand Hyatt in New York City.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the groundbreaking results of the REG1 phase 2b trial (RADAR).  Additionally, a summary of the positive results of the FDA end-of-phase 2 meeting and a description of the resulting phase 3 development program and timeline, minimized for cost and maximized for probability of success, will be provided.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3 
Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS
Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the complementary specific active control agent of pegnivacogin. 

More information can be found at www.regadobio.com

Contact:  Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.com

Media Contact:
Tiberend Strategic Advisors, Inc.
1-212-827-0020
Andrew Mielach, amielach@tiberend.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
2. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
3. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
5. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
9. Thoratec Announces Presentations At Upcoming Investor Conferences
10. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
11. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):